Glecaprevir/Pibrentasvir Induced Cholestatic Jaundice in a HCV Patient with Renal Failure. A Case Presentation

Author(s): Benedetto Caroleo, Maria Cristina Caroleo, Antonio Cimellaro, Lidia Colangelo, Maria Perticone, Giulio Di Mizio, Giovambattista De Sarro, Luca Gallelli*.

Journal Name: Current Drug Safety

Volume 14 , Issue 1 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: Direct-acting Antivirals (DAA) are currently used in the treatment of chronic HCV infection. In patients with renal failure Glecaprevir/Pibrentasvir (genotype 1-6) is recommended for its safety and efficacy.

Case Presentation: Although these pharmacological characteristics, an adverse drug reaction (ADR) has been reported during Glecaprevir/Pibrentasvir treatment, such as the development of cholestatic jaundice in an elderly patient with chronic HCV (genotype 2) infection. At examination, patient was jaundiced associated with intense pruritus.

Results: Ultrasound and laboratory biochemical tests excluded a liver failure (e.g. liver cancer, and liver lithiasis) or pancreatic cancer while Naranjo probability scale (score 6) suggested an association between cholestatic jaundice and Glecaprevir/Pibrentasvir administration. About 1 month after drug discontinuation, an improvement has been documented in both jaundice and pruritus, with a normalization in bilirubin levels (total bilirubin: 0.96 mg/dL), HCV-RNA was undetected also. It is worth mentioning that although we reported the development of cholestatic jaundice upon treatment with Glecaprevir/Pibrentasvir we recorded a clinical efficacy (HCV-RNA <15 IU/L) after 4 weeks from the beginning of the treatment, with a complete remission of clinical symptoms until 7 months after drug discontinuation.

Conclusion: These data support the clinical efficacy of Glecaprevir/Pibrentasvir association in elderly patients, despite the sub-optimal period of treatment.

Keywords: Direct-acting antiviral, HCV, cholestatic jaundice, GFR, SVR, glecaprevir/pibrentasvir.

[1]
Crouchet E, Wrensch F, Schuster C, Zeisel MB, Baumert TF. Host-targeting therapies for hepatitis C virus infection: Current developments and future applications. Therap Adv Gastroenterol 2018; 11: 1756284818759483.
[2]
Liang TJ, Ghany MG. Current and future therapies for hepatitis C virus infection. N Engl J Med 2013; 368(20): 1907-17.
[3]
Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365(11): 1014-24.
[4]
Poordad F, McCone J, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364(13): 1195-206.
[5]
Dubin PH, Sclair SN, Rico R, et al. Low SVR rates in clinical practice for treating genotype 1 chronic hepatitis C with protease inhibitors boceprevir and telaprevir. Dig Dis Sci 2015; 60(1): 272-4.
[6]
Bourliere M, Gordon SC, Flamm SL, et al. Sofosbuvir, Velpatasvir, and Voxilaprevir for previously treated HCV infection. N Engl J Med 2017; 376(22): 2134-46.
[7]
Bourliere M, Gordon SC, Schiff ER, et al. Deferred treatment with sofosbuvir-velpatasvir-voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: An open-label substudy of POLARIS-1. Lancet Gastroenterol Hepatol 2018; 3(8): 559-65.
[8]
Ng TI, Krishnan P, Pilot-Matias T, et al. In Vitro antiviral activity and resistance profile of the Next-Generation hepatitis C virus ns5a inhibitor pibrentasvir. Antimicrob Agents Chemother 2017; 61(5): pii: e02558-.
[9]
Ng TI, Tripathi R, Reisch T, et al. In Vitro antiviral activity and resistance profile of the Next-Generation Hepatitis C virus ns3/4a protease inhibitor glecaprevir. Antimicrob Agents Chemother 2018; 62(1): pii: e01620-.
[10]
Poordad F, Felizarta F, Asatryan A, et al. Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment. Hepatology 2017; 66(2): 389-97.
[11]
Poordad F, Pol S, Asatryan A, et al. Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure. Hepatology 2018; 67(4): 1253-60.
[12]
Puoti M, Foster GR, Wang S, et al. High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1-6 patients without cirrhosis. J Hepatol 2018; 69(2): 293-300.
[13]
Caroleo B, Gallelli L, Staltari O, De Sarro G, Guadagnino V. Serum transaminase elevations during pegylated interferon treatment of chronic HCV hepatitis probably induced by polyethylene glycol. Intervirology 2008; 51(6): 407-9.
[14]
Gallelli L, Staltari O, Palleria C, De Sarro G, Ferraro M. Hepatotoxicity induced by methimazole in a previously healthy patient. Curr Drug Saf 2009; 4(3): 204-6.
[15]
Gallelli L, De Fazio S, Corace E, De Sarro G, Garcia CS, De Fazio P. Generalised urticaria in a young woman treated with clomipramine and after ingestion of codfish. Pharmacopsychiatry 2006; 39(4): 154-6.
[16]
Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30(2): 239-45.
[17]
Gallelli L, Colosimo M, Pirritano D, et al. Retrospective evaluation of adverse drug reactions induced by nonsteroidal anti-inflammatory drugs. Clin Drug Investig 2007; 27(2): 115-22.
[18]
Gallelli L, Ferreri G, Colosimo M, et al. Retrospective analysis of adverse drug reactions to bronchodilators observed in two pulmonary divisions of Catanzaro, Italy. Pharmacol Res 2003; 47(6): 493-9.
[19]
Hubbard H, Lawitz E. Glecaprevir + pibrentasvir (ABT493 + ABT-530) for the treatment of Hepatitis C. Expert Rev Gastroenterol Hepatol 2018; 12(1): 9-17.
[20]
Carrion AF, Martin P. Glecaprevir + pibrentasvir for treatment of hepatitis C. Expert Opin Pharmacother 2018; 19(4): 413-9.
[21]
Abutaleb A, Kottilil S, Wilson E. Glecaprevir/pibrentasvir expands reach while reducing cost and duration of hepatitis C virus therapy. Hepatol Int 2018; 12(3): 214-22.
[22]
Asselah T, Kowdley KV, Zadeikis N, et al. Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 weeks in patients with hepatitis C virus genotype 2, 4, 5, or 6 infection without cirrhosis. Clin Gastroenterol Hepatol 2018; 16(3): 417-26.
[23]
Toyoda H, Chayama K, Suzuki F, et al. Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection. Hepatology 2017; 66(1): S528.
[24]
Reau N, Kwo PY, Rhee S, et al. Glecaprevir/Pibrentasvir Treatment in Liver or kidney transplant patients with hepatitis C virus infection. Hepatology 2018; 68(4): 1298-307.
[25]
Kumada H, Watanabe T, Suzuki F, et al. Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection. J Gastroenterol 2018; 53(4): 566-75.
[26]
Nappi A, Perrella A, Bellopede P, et al. Safety of new DAAs for chronic HCV infection in a real life experience: Role of a surveillance network based on clinician and hospital pharmacist. Infect Agent Cancer 2017; 12: 12.
[27]
Barritt ASt, Fried MW. Maximizing opportunities and avoiding mistakes in triple therapy for hepatitis C virus. Gastroenterology 2012; 142(6): 1314-23.
[28]
Caroleo B, Staltari O, Gallelli L, Perticone F. Reactivation of chronic hepatitis B during treatment with tenofovir disoproxil fumarate: Drug interactions or low adherence? BMJ Case Rep 2015; 2015: pii: bcr2015209586.
[29]
Postnikova OA, Nepomnyashchikh GI, Yudanov AV, Nepomnyashchikh DL, Kapustina VI, Isayenko VI. Intracellular cholestasis in HCV and HBV infection. Bull Exp Biol Med 2012; 153(6): 898-901.
[30]
EASL. Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 2017; 67(2): 370-98.
[31]
US Food and Drug Administration. FDA Drug Safety Communication: FDA warns about the risk of hepatitis B reactivating in some patients treated with direct-acting antivirals for hepatitis C. [Accessed August 10, 2017]. https://www.fda.gov/Drugs/ DrugSafety/ucm522932.htm 2016. Published October 4, 2016. Updated October 12, 2016.
[32]
American Association for the Study of Liver Diseases; Infectious Diseases Society of America. HCV guidance: Recommendations for testing, managing, and treating hepatitis C. Available from: http://www.hcvguidelines.org 2018.
[33]
Pockros PJ. Black box warning for possible HBV reactivation during DAA therapy for chronic HCV infection. Gastroenterol Hepatol (N Y) 2017; 13(9): 536-40.
[34]
Assy N, Jacob G, Spira G, Edoute Y. Diagnostic approach to patients with cholestatic jaundice. World J Gastroenterol 1999; 5(3): 252-62.
[35]
Fernandez-Murga ML, Petrov PD, Conde I, Castell JV, Gomez-Lechon MJ, Jover R. Advances in drug-induced cholestasis: Clinical perspectives, potential mechanisms and in vitro systems. Food Chem Toxicol 2018; 120: 196-212.
[36]
Chatterjee S, Annaert P. Drug-induced cholestasis: Mechanisms, models, and markers. Curr Drug Metab 2018; 19(10): 808-18.
[37]
Mergener K, Enns R, Eubanks WS, Baillie J, Branch MS. Pseudo-Mirizzi syndrome in acute cholecystitis. Am J Gastroenterol 1998; 93(12): 2605-6.
[38]
Pasanen PA, Partanen KP, Pikkarainen PH, Alhava EM, Janatuinen EK, Pirinen AE. A comparison of ultrasound, computed tomography and endoscopic retrograde cholangiopancreatography in the differential diagnosis of benign and malignant jaundice and cholestasis. Eur J Surg 1993; 159(1): 23-9.
[39]
Crawford JM. Cellular and molecular biology of the inflamed liver. Curr Opin Gastroenterol 1997; 13: 175-85.
[40]
Chan KM, Cheng CH, Wu TH, et al. De Novo Endotoxin-Induced production of antibodies against the bile salt export pump associated with bacterial infection following major hepatectomy. BioMed Res Int 2018; 2018: 6197152.
[41]
Spitzer JA, Zhang P. Hepatic cellular interactions in endotoxaemia and sepsis. Biochem Soc Trans 1995; 23(4): 993-8.
[42]
Uhl B, Speth V, Wolf B, Jung G, Bessler WG, Hauschildt S. Rapid alterations in the plasma membrane structure of macrophages stimulated with bacterial lipopeptides. Eur J Cell Biol 1992; 58(1): 90-8.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 14
ISSUE: 1
Year: 2019
Page: [67 - 71]
Pages: 5
DOI: 10.2174/1574886313666181116100452
Price: $65

Article Metrics

PDF: 56
HTML: 2
EPUB: 1
PRC: 1